tetracyclines, pentamidine, methapyrilene, budenoside, flunisolide, tipredane, triamcinolone acetonide, noscapine, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropenolamine, pirbuterol, reproterol, rimeterol, terbutaline, isoetharine, tulobuterol, orciprenaline, (-)-4-amino-3,5-dichloro-a-[[[6-[-2-(2-pyridinyl)ethoxy]hexyl]-amino]methyl]benzenemethanol, amiloride, ipratropium, atropine, oxitropium, cortisone, hydrocortisone, prednisolone, aminophylline, choline theophyllinate, lysine theophyllinate, theophylline, insulin, glucagon and any mixtures thereof.

19. A pharmaceutical powder composition according to claim 18, wherein said at least one lactose pellet has a diameter of from about 150 to 1000 micrometers.

20. A pharmaceutical powder composition according to claim 18, wherein at least about 90% by weight of the microfine particles of lactose have a diameter of less than about 15 micrometers.

21. A pharmaceutical powder composition according to claim 18, wherein said at least one lactose pellet is hard or soft.

22. A pharmaceutical powder composition according to claim 21, wherein the soft lactose pellet has a crushing weight of about 50 to about 500 mg as determined by the crushing test described herein.

23. A pharmaceutical powder composition according to claim 22, wherein the soft lactose pellet has a crushing weight of about 50 to about 100 mg as determined by the crushing test described herein.

24. A pharmaceutical powder composition according to claim 18, wherein the medicament is ~~turbutaline sulphate.~~ terbutaline sulphate

25. A pharmaceutical powder composition according to claim 18, wherein the medicament is formoterol.

26. A pharmaceutical powder composition according to claim 18, wherein the medicament is budenoside.

27. A pharmaceutical powder composition according to claim 18, wherein the medicament comprises a mixture of formoterol and budenoside.

28. A pharmaceutical composition according to claim 18, wherein the microfine particles of medicament form at least one medicament pellet.

29. A process for preparing a pharmaceutical composition according to claim 18, comprising admixing microfine particles of medicament with at least one lactose pellet having a diameter of from about 10 to about 1500 micrometers, which pellet comprises a plurality of microfine lactose particles.

30. A process according to claim 29, wherein the admixing comprises coating the lactose pellets with a liquid suspension or solution of medicament.

31. An inhalation device comprising a ~~compound~~ composition according to claim 18.

32. A composition according to claim 18, wherein the medicament is selected from the group consisting of anti-allergics, bronchodilators, anti-inflammatory steroids and mixtures thereof, for use in the treatment of respiratory disorders.

33. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical powder composition which comprises microfine particles of medicament selected from the group consisting of anti-allergics, bronchodilators, anti-inflammatory steroids and mixtures thereof and at least

one lactose pellet having a diameter of from about 10 to about 1500 micrometers, which pellet comprises a plurality of microfine lactose particles.

34. A pharmaceutical powder composition according to claim 18, wherein said at least one lactose pellet has a diameter of from about 150 to 1000 micrometers, and wherein at least about 90% by weight of the microfine particles of lactose have a diameter of less than about 15 micrometers.

35. A pharmaceutical powder composition according to claim 34, wherein the soft lactose pellet has a crushing weight of about 50 to about 500 mg as determined by the crushing test described herein.

36. A pharmaceutical powder composition according to claim 35, wherein the medicament is selected from the group consisting of salmeterol xinafoate, salbutamol sulphate and fluticasone propionate.

37. A pharmaceutical powder composition according to claim 24, wherein the medicament is selected from the group consisting of salmeterol xinafoate, salbutamol sulphate and fluticasone propionate.

38. A pharmaceutical powder composition ~~according to claim 18, wherein~~ said at least one lactose pellet ~~has~~ a diameter form about 150 to 1000 micrometers and wherein at least ~~about~~ 90% by way of the microfine particles of lactose have a diameter of less than about 15 micrometers and wherein the lactose pellet is a soft lactose pellet having a crushing weight of about 50 to about 150 mg as determined by the crushing test described herein.

39. A pharmaceutical powder composition according to claim 38, wherein the soft lactose pellet has a crushing weight of about 50 to about 100 mg.- -